At present, several trials are exploring different BsAbs combined with various anti-MM agents—including IMiDs, PIs, anti-CD38 mAbs, and/or anti-PD1 inhibitors—or with agents that enhance the expression of target antigens or are evaluating the combination of BsAbs directed against different targets. Here, CD38 is linked to Miyoshi myopathy.